Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer

Stephen E. Jones, Robert G. Mennel, George N. Peters, Mary Alice Westrick, Barry D. Brooks, Sally Moot Knox, Patty McGuffey

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients with Stage 2 (node positive) breast cancer. Doses of C and F were 600 mg/m2 and E was 75 mg/m2. Moderate granulocytopenia (median count = 610/mm3) occurred on day 14 of the first 21 day treatment course and was the main toxicity encountered with treatment, although there were no episodes of granulocytopenic fever. Grade 3 or 4 vomiting occurred in 40% and significant alopecia in 30% of patients. Four patients experienced transient asymptomatic decreases in calculated radionuclide cardiac ejection fraction of ≥ 10% but no signs or symptoms of cardiac failure were observed. If epirubicin proves to be less cardiotoxic than doxorubicin, this combination would merit further evaluation as potential adjuvant therapy for early breast cancer.

Original languageEnglish (US)
Pages (from-to)195-198
Number of pages4
JournalInvestigational New Drugs
Volume6
Issue number3
DOIs
StatePublished - Sep 1 1988

Keywords

  • 5-fluorouracil
  • adjuvant chemotherapy
  • cyclophosphamide
  • epirubicin

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer'. Together they form a unique fingerprint.

Cite this